CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

02 Mar 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021

24 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021

23 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

16 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

08 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

12 Jan 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

06 Jan 2021 07:05:00 By Nasdaq GlobeNewswire